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Schizophrenia (SZ) is a severe psychiatric illness associ-
ated with an elevated risk for developing Alzheimer’s disease 
(AD). Both SZ and AD have white matter abnormalities and 
cognitive deficits as core disease features. We hypothesized 
that aging in SZ patients may be associated with the devel-
opment of cerebral white matter deficit patterns similar to 
those observed in AD. We identified and replicated aging-
related increases in the similarity between white matter def-
icit patterns in patients with SZ and AD. The white matter 
“regional vulnerability index” (RVI) for AD was signifi-
cantly higher in SZ patients compared with healthy con-
trols in both the independent discovery (Cohen’s d = 0.44, 
P  =  1·10–5, N  =  173 patients/230 control) and replication 
(Cohen’s d = 0.78, P = 9·10–7, N = 122 patients/64 controls) 
samples. The degree of overlap with the AD deficit pattern 
was significantly correlated with age in patients (r = .21 and 
.29, P < .01 in discovery and replication cohorts, respectively) 
but not in controls. Elevated RVI-AD was significantly asso-
ciated with cognitive measures in both SZ and AD. Disease 
and cognitive specificities were also tested in patients with 
mild cognitive impairment and showed intermediate overlap. 
SZ and AD have diverse etiologies and clinical courses; our 
findings suggest that white matter deficits may represent a 
key intersecting point for these 2 otherwise distinct diseases. 
Identifying mechanisms underlying this white matter def-
icit pattern may yield preventative and treatment targets for 
cognitive deficits in both SZ and AD patients.
Key words:  white matter deficit pattern/schizophrenia/
Alzheimer’s disease/dementia
Introduction 
Compared with the general population, individuals with 
schizophrenia (SZ) have a significantly higher risk (2–4 
times) of developing Alzheimer’s disease (AD) and other 
dementias.1 As the hallmark neuropathological features 
of AD are not typically found in younger SZ patients,2,3 
this elevated risk for AD remains unexplained. Literature 
on this topic inevitably invokes Kraepelin’s one-hundred-
year-old term dementia praecox, describing the intellec-
tual decline and observed neurodegeneration in some 
SZ postmortem examinations.4 However, the historical 
definition of SZ5,6 and the modern epidemiological lit-
erature1,7 do not offer a mechanistic explanation for the 
higher rate of AD development in SZ patients.
Patients with AD and SZ both express complex ana-
tomical and cognitive deficits but with nonoverlapping 
clinical presentations. AD is characterized by a relatively 
rapid progression with illness onset occurring during the 
sixth to eighth decades of life. In contrast, SZ typically 
emerges between late adolescence and early adulthood 
with rapid worsening of cognitive deficits following illness 
onset and a gradual aging-related decline afterward.8–10 
The dominating etiological pathways for SZ and AD 
are likewise nonoverlapping. The prevailing hypothesis 
in AD posits neuronal atrophy due to the accumulation 
of β-amyloid (Aβ) plaques and τ-neurofibrillary tangles. 
The prevailing hypotheses in SZ are dysfunctions in the 
dopamine, glutamate, and other neurotransmitter cir-
cuits.11–13 AD and SZ are distinct in their clinical presen-
tations; however, we may have overlooked an important 
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shared feature between AD and SZ such as the profound 
white matter impairment in both illnesses.
Despite etiological and clinical differences, impaired 
brain white matter microstructure, measured as a re-
duction in fractional anisotropy (FA) derived from dif-
fusion tensor imaging (DTI), is prominent in both 
disorders: white matter deficits are present before dis-
ease onset and track with the rise in cognitive decline 
and symptom severity.10,14–16 In AD, the illness-related 
pathology is characterized by distinct temporal and re-
gional patterns that track with the accumulation of Aβ 
plaques and τ-neurofibrillary tangles.17 AD pathology is 
considered a direct factor in axonal damage and the re-
gional specificity of FA deficits, independent of age and 
hyperintensive white matter lesion burden.18 Reduced FA 
values in pathways serving higher cognitive function are 
associated with higher cognitive deficits in AD.16 In SZ, 
regional FA deficits also occur in specific temporal and 
regional patterns that precede symptoms and are asso-
ciated with cognitive deficits.19–30 A  large and inclusive 
meta-analytic SZ study performed by the Enhancing 
Neuro Imaging Genetics Meta-Analysis (ENIGMA) 
consortium showed that patients have reproducible and 
stable patterns of white matter deficits.31 Here, we aimed 
to evaluate the similarity of the white matter deficit pat-
terns between AD and SZ as a potential explanation for 
the higher risk of developing AD in SZ patients.
To capture the similarity between white matter deficit 
patterns, we calculated a white matter regional vulnera-
bility index (RVI)32 for AD using data from the Alzheimer’s 
Disease Neuroimaging Initiative (ADNI). RVI quantifies 
the similarity between white matter patterns of any indi-
vidual and the deficit pattern observed in AD. We tested 
the hypothesis that SZ patients have elevated RVI scores 
for AD in independent discovery, replication, and meta-
analytical samples. We tested specificity by contrasting 
deficit patterns in AD with patterns in mild cognitive im-
pairment (MCI). MCI has elevated risks for developing 
AD but itself is not AD; thus, we used the similarity to 
MCI as a control for testing age-related anatomical deficits 
that are AD specific. We further tested a reverse associa-
tion by showing elevated SZ white matter deficit patterns 
in AD patients. Finally, we tested the hypothesis that RVI-
defined white matter patterns impact the cognitive deficits 
most characteristic of SZ and AD.
Materials and Methods
Sample Characteristics
The AD and MCI deficit patterns were derived from 
datasets collected and distributed by the ADNI. We 
chose 3 independent SZ samples: a sample of patients 
and controls from the Baltimore, MD area to serve as 
the discovery sample; a sample of patients and controls 
from Beijing, China, to serve as the replication sample; 
and a meta-analytical sample assessed by ENIGMA-SZ 
workgroup to serve as another replication sample. The 
ethnic and geographical diversity of these samples was 
meant to reduce cohort-specific variances in diagnosis, 
treatment, and other factors. All DTI data were processed 
using a consistent ENIGMA-DTI workflow33 and passed 
comprehensive QA and QC steps. Detailed demographic 
(supplementary tables S1 and S2) and imaging informa-
tion (supplementary table S3) are in the supplementary 
information. Briefly:
ADNI Samples: AD and MCI. We downloaded demo-
graphic, diagnostic, and imaging data for participants in 
ADNI-2 protocols (http://adni.loni.usc.edu). The details of 
the site and imaging protocols are provided in the SI. The DTI 
data passed ENIGMA QA/QC steps for 218 participants. 
This sample included 53 healthy controls (M/F  =  24/29, 
age = 72.77 ± 7.57), 117 MCI (M/F = 73/44, age = 72.70 ± 
7.67), and 48 AD (M/F = 29/19, age = 72.57 ± 7.67) pa-
tients. The cognitive data included: Mini Mental Status 
Examination (MMSE),34 Clinical Dementia Rating Scale 
Sum-of-Boxes (CDR-SOB),35 and Alzheimer’s Disease 
Assessment Scale-Cognitive subscale (ADAS-Cog).36
Discovery Sample. The sample consisted of 173 SZ pa-
tients (M/F = 122/51, age = 36.0 ± 12.7) and 210 con-
trols (M/F = 119/111, age = 38.2 ± 13.0) from the Greater 
Baltimore area for whom DTI data passed ENIGMA 
QA/QC requirements. Patients were recruited from 
community psychiatric clinics and diagnosed with ei-
ther DSM-IV schizophrenia or schizoaffective disorder. 
Controls had no Axis I  psychiatric disorder. Cognition 
was evaluated by the Digit Symbol Coding task of 
the WAIS-337 to assess processing speed and the Digit 
Sequencing Test38 to assess working memory (supplemen-
tary table S2). The clinical and DTI protocol information 
have been reported9 and are further described in SI.
Replication Sample. The sample consisted of 122 
SZ patients (M/F  =  57/65, 38.2  ± 13.3) and 78 con-
trols (M/F = 37/41, 39.2 ± 14.0), recruited from Beijing 
Huilongguan Hospital, Beijing, China for whom DTI 
data passed ENIGMA QA/QC requirements. Controls 
were recruited through local advertisements. Patients met 
DSM-IV criteria for SZ, and all participants were Han 
Chinese. DTI data were collected using a 3T Siemens 
MRI scanner. The clinical and DTI protocol information 
have been reported32 and are further described in SI.
Meta-Data Replication Sample From ENIGMA. The 
worldwide aggregate data from the largest meta-analysis 
of DTI in SZ performed by ENIGMA39 were used as 
the second replication sample. This sample consisted of 
1963 SZ patients and 2359 controls from 29 international 
studies.39 The clinical, DTI, and harmonization informa-
tion have been described previously.39
Image Processing
DTI data for all cohorts were processed uniformly using 
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org/projects/enigma_dti)33; details are described in SI. 
The per-tract effect size for the FA, shown in figure  1 
(see legend for tract names), was calculated by averaging 
values along tract regions of interest in both hemispheres. 
All data were corrected for age, sex, and age by sex in-
teraction during normalization to increase compatibility 
among the cohorts.
Statistical Analysis
RVI Calculation. The RVI is a simple measure of  the 
similarity between an individual and the expected deficit 
pattern derived from a representative disease sample.31,32 
In this study, it is calculated as a correlation between 
an individual’s pattern of  FA in the 22 white matter re-
gions and the expected pattern of  a disease condition. 
Regional FA for each tract was z-normalized by cal-
culating the residual values after the regression of  age 
and sex effects, and then subtracting the average value 
for a region and dividing it by the standard deviation 
calculated from the sample’s healthy controls. This pro-
duced a vector of  z-values with 22 regional values for 
every individual. The ADNI sample was used to calcu-
late Cohen’s d effect sizes for AD and MCI patients vs 
controls (figure 1A). RVI-AD is a scalar correlation co-
efficient between region-wise z values for the individual 
and the AD-control effect sizes. Higher RVI values in 
SZ patients would imply a higher similarity of  the white 
matter regional deficit patterns in SZ toward that of 
AD. RVI-SZ was calculated using effect sizes from the 
ENIGMA sample.39
Hypothesis Testing. Effect sizes of white matter FA in 
AD and MCI calculated from the ADNI sample were 
used to derive RVI-AD and RVI-MCI in SZ patients and 
controls. Hypothesis testing was performed in 3 steps: (1) 
Testing if  RVI-AD is elevated in SZ patients in the dis-
covery sample, followed by confirmatory testing in 2 rep-
lication cohorts and age-group analysis; specificity testing 
was performed using RVI-MCI values. (2) Testing the re-
verse association where RVI-SZ based on the ENIGMA 
SZ pattern is significantly elevated in AD patients; speci-
ficity testing was performed in MCI patients. (3) Testing 
that RVI-AD is associated with cognitive deficits in AD 
patients and SZ patients.
The age-group analysis was tested by dividing the dis-
covery and replication cohorts into 4 age groups: 18–29, 
30–39, 40–49, and 50–65 (supplementary table S5) and 
evaluating patient-control differences within each age 
category.
The associations between RVI and cognition were 
tested using a linear model:
Cognition ∼ A + βsz · DXszor βAD · DXAD
+ βRVI−AD · RVI − ADor βRVI−SZ · RVI − SZ
where “cognition” stands for the cognitive measures and 
DX for diagnosis (coded as follows: in the SZ sample: 
SZ = 1, control = 0; in the ADNI sample: AD = 1, con-
trol = 0). Collinearity was examined using the variance 
inflation factor (<5.0 is deemed acceptable). Effects of 
symptoms, antipsychotic medication dose, and smoking 
Fig. 1. The pattern of white matter microstructural deficits across 22 white matter regions as ranked by their Cohen’s d effect sizes 
(patients < controls) in fractional anisotropy in each sample. The tabulated statistics are presented in supplementary table S5. The 
black line indicates the best linear fit for each disease; regional vulnerability index (RVI) (eg, for AD) is essentially a calculation of the 
correlation coefficient between this line for AD and the FA of these 22 regions in an individual. Note: ACR, Anterior Corona Radiata; 
ALIC, Anterior Limb of Internal Capsule; BCC, Body of Corpus Callosum; CC, Corpus Callosum; CGC, Cingulum; CR, Corona 
Radiata; CST, Cortico-Spinal Tract; EC, External Capsule; FX, Fornix, GCC, Genu of Corpus Callosum, IC, Internal Capsule; IFO, 
Inferior Frontal Occipital fasciculus; PCR, Posterior Corona Radiata; PLIC, Posterior Limb of Internal Capsule; PTR, Posterior 
Thalamic Radiation; RLIC, Retrolenticular Limb of the Internal Capsule; SCC, Splenium of Corpus Callosum; SCR, Superior Corona 
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status (modeled as current smokers or not) were similarly 
explored in regression analyses. Group comparisons of 
RVI values were performed by ANOVA. All statistical 
significance thresholds were corrected for multiple com-
parisons by false discovery rates (FDR).
Results
Patterns of Regional White Matter Deficits in AD, 
MCI, and SZ
Five samples were analyzed to test the above hypoth-
eses—the ADNI samples40 for AD and MCI and 3 SZ 
samples—a discovery sample from Baltimore, MD; a 
replication sample from Beijing, China; and a replication 
sample from the worldwide meta-sample from ENIGMA, 
which is the largest white matter imaging sample in SZ.41 
Each sample had its own healthy controls. Details on 
sample size, demographic (supplementary tables S1 and 
S2), and imaging (supplementary table S3) information 
are in the Methods section and supplementary informa-
tion. White matter microstructures were measured by FA 
of DTI. The ranks of regional FA effect sizes between pa-
tients and controls for each cohort are shown in figure 1 
and supplementary table S4. In AD, the largest effect 
sizes were in the fornix (FX) followed by the splenium of 
the corpus callosum (SCC) (figure 1A). In MCI, the lar-
gest effect sizes were in the SCC and FX (figure 1B). In 
the 3 SZ cohorts, patients showed the largest effect sizes 
in the anterior corona radiata (ACR), anterior limb of 
the internal capsule (ALIC), FX, and body of the corpus 
callosum (BCC) (figures  1C–E). The regional patient-
control effect sizes in the discovery and replication co-
horts were significantly correlated with those reported by 
ENIGMA (r =  .94 and .85, P < .01, for discovery and 
replication cohorts, respectively).
Elevated White Matter RVI-AD in SZ in the 
Discovery Sample
SZ patients had significantly higher RVI-AD than con-
trols (Cohen’s d = 0.44, t = 4.5, P = 1·10–5) figure 2A). 
RVI-AD showed significant and positive Spearman cor-
relations with age in SZ patients (r = .21, P < .001) but 
not in controls (r = −.03, P = .8). SZ patients had signifi-
cantly higher RVI-AD compared with controls starting at 
age 30 (figure 3A).
Elevated White Matter RVI-AD in SZ in the 
Replication Sample
SZ patients again showed significantly higher RVI-AD 
than controls (Cohen’s d  =  0.78, t  =  5.1, P  =  9·10–7) 
(figure 2B). There were no significant differences between 
the discovery and replication cohorts in RVI-AD (P = .07) 
(compare figure 2A vs 2B). SZ patients had significantly 
higher RVI-AD compared with controls starting at age 
40 (figure  3A). The significant correlations of RVI-AD 
with age were also replicated in SZ patients (r = .29, P < 
.001) (figure 3B). The correlation between RVI-AD and 
age was not significant in controls (r = .18, P = .2).
Replication of Elevated White Matter RVI-AD in SZ 
Using ENIGMA Sample
The ENIGMA SZ pattern of regional white matter 
deficits was significantly correlated with the pattern for 
white matter deficits in AD (r = .55, P = .01) (figure 4A). 
The RVI-AD (calculated from ADNI) and RVI-SZ (cal-
culated from ENIGMA) in SZ patients were highly 
correlated (r  =  .65, P  =  10–25) (figure  4C). Therefore, 
despite the very different age ranges, etiologies, and 
neuropathologies, the white matter deficit patterns in SZ 
patients showed significantly elevated similarity to white 
Fig. 2. Patient-control differences in the average RVI-AD and RVI-MCI values for the discovery and replication cohorts. Note: RVI, 






/schizophreniabulletin/article/47/1/197/5873334 by guest on 25 February 2021
201
White Matter Schizophrenia and Alzheimer’s Disease
matter deficit patterns observed in AD patients across the 
samples.
Relative Specificity Testing by Comparing With MCI
SZ patients also showed elevated RVI-MCI in both the 
discovery (t  =  3.3, P  =  .002) and replication sample 
(t = 3.8, P = 2·10–4) (figure 2B). The ENIGMA SZ pat-
tern of white matter deficits was not significantly cor-
related with those in MCI (r =  .10, P =  .6) (figure 4B). 
The correlation between RVI-MCI and RVI-SZ was also 
significant (r = .31, P = 10–4) (figure 4D) but the r value 
was significantly smaller than the correlation between 
RVI-AD and RVI-SZ (z test of the correlation coeffi-
cients = 3.5, P = 4·10–4).
Testing the Reverse Association: Elevated RVI-SZ in AD
RVI-SZ values were derived from the ENIGMA SZ 
sample and used to calculate RVI-SZ in AD and MCI 
patients and controls in ADNI. RVI-SZ was significantly 
higher in AD patients compared with MCI patients 
(P  =  .009) and normal controls (P  =  8·10–5) (average 
RVI-SZ = 0.15 ± 0.04, 0.00 ± 0.3, and −0.06 ± 0.4 for AD, 
MCI, and controls, respectively). MCI patients showed 
no significant difference in average RVI-SZ values com-
pared with controls (P = .21).
RVI-AD on Cognition and Clinical Characteristics
Processing speed has been considered the cognitive 
measure most robustly associated with schizophrenia42,43 
and schizophrenia-related white matter deficits.9,44 We 
found that RVI-AD significantly correlated with proc-
essing speed in the discovery (r = −.34, P = 1·10–4) and 
replication samples (r  =  −.27, P  =  2·10–4). One of the 
standard tests for cognitive deficits for AD is the ADAS-
Cog.45 RVI-AD was significantly and positively cor-
related with the ADAS-Cog in the full ADNI sample 
(r  =  .42, P  =  10-10). Interestingly, RVI-SZ was also sig-
nificantly correlated with ADAS-Cog in the full ADNI 
sample (r  =  .33, P  =  1·10–6). Finally, psychiatric symp-
toms were measured in the discovery and replication sam-
ples using the Brief  Psychiatric Rating Scale (BPRS). No 
significant associations between RVI-AD and BPRS total 
or any subscale scores were detected (all r < .1, P > .20). 
There were also no significant effects of current antipsy-
chotic medication dosage or current smoking status (all 
P > .15) on the RVI-AD scores in the discovery or repli-
cation datasets.
Discussion
Cognitive enhancing compounds have been tested as pro-
spective frontline treatments for both SZ and AD but the 
effort has thus far has met with costly failure.46 Identifying 
the overlapping pathophysiological mechanisms for cog-
nitive deficits in SZ and AD may guide and focus research 
on effective treatments that target the shared deficits be-
tween them. We observed a striking similarity between 
white matter deficit patterns in SZ and AD that are both 
replicable and associated with core cognitive deficits in the 
respective illnesses. The RVI-AD values were positively 
correlated with age in patients but not in controls. Patients 
started to show significantly higher RVI-AD in the fourth 
Fig. 3. Significant age-related increases of RVI-AD values for schizophrenia (SZ) (A and B). *Significant after false discovery rates 
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decade of life in the discovery cohort and during the fifth 
decade in the replication cohort. In all 3 datasets (dis-
covery, replication, and ADNI), higher RVI-AD values 
were associated with worse neurocognitive performance. 
Our findings propose bringing white matter-related bio-
markers to the forefront of efforts to identify treatment 
targets for cognitive deficits in both illnesses.
The significant correlation of white matter patient-
control regional effect size patterns between SZ and AD 
was driven by a significant reduction in the integrity of the 
associative white matter tracts, including the ACR, FX, 
and commissural fibers in the genu of corpus callosum 
(GCC) and BCC while relatively sparing the motor and 
sensory fibers such as the corticospinal tract and posterior 
limb of the internal capsule in both SZ and AD (figure 1). 
ACR, GCC, and BCC contain the primary fibers con-
necting the ipsilateral and interhemispheric prefrontal 
cortex and are critical for higher cognitive functions. 
Among all brain regions, the frontal white matter volume 
had the largest evolutionary increase in humans compared 
with other species,47 implying that the regions showing the 
strongest impairment in both SZ and AD (figure 4C) are 
also the phylogenetically most-expanded brain tissue in 
humans. The FX is another associative fiber with substan-
tial impairment in both SZ and AD. The FX fiber-tract 
links the hippocampus with the lateral hypothalamus and 
frontal cortical regions. Hippocampal shrinkage is a hall-
mark of AD,48,49 and hippocampal volume in SZ shows 
the largest reduction among all subcortical regions.50 
These neurobiological signatures common to SZ and AD 
may explain their associations with similar regional deficit 
patterns captured by the RVI approach.
RVI is a simple correlation between an individual and 
the expected deficit pattern derived from a representa-
tive disease sample.32 The RVI is calculated after cor-
recting the regional traits for age and sex. Therefore, the 
Fig. 4. On white matter tract level (A and B): A. Significant correlation of regional deficit (in Cohen’s d values) patterns across the 22 
major white matter tracts for Alzheimer’s disease (AD; calculated from ADNI) and schizophrenia (SZ; calculated from ENIGMA). B. 
No such correlation was observed between MCI and SZ. Similarly, on individual SZ patient level (C and D): C. regional vulnerability 
index (RVI) for AD (calculated from ADNI) and RVI for SZ (calculated from ENIGMA) showed a robust correlation in SZ patients 
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aging-related increases in RVI-AD in patients support 
the heuristics of SZ as a progressive neurological disease 
with an elevated risk of dementia.51–58 These heuristics are 
further supported by evidence for the accelerated decline 
of the associative white matter tracts in patients with 
SZ.30,59,60 Thus, the higher white matter RVI-AD in SZ 
patients is likely associated with detrimental interactions 
between SZ risk factors and aging of cerebral white 
matter. RVI does not measure the underlying neurobio-
logical mechanisms. However, because RVI quantifies the 
similarity of the anatomic deficit pattern to the represen-
tative disease pattern, it can capture shared brain deficit 
patterns between different diseases and allow for the in-
ference of intersecting anatomic mechanisms.
The hypothesis of similarity in the underlying mech-
anisms for the shared white matter deficits between AD 
and SZ is still a subject to debate. Contemporary med-
icine has largely dismissed Kraepelin’s definition of SZ 
as premature dementia61 due to the lack of evidence for 
neurodegenerative cognitive decline in most SZ patients.6 
The lack of amyloid-β and τ-protein pathologies in most 
SZ postmortem studies further suggests nonoverlapping 
pathophysiology.2,3 Despite these clear etiopathological 
differences, neuroimaging studies have shown similarities 
in deficits patterns between AD and SZ. For example, an-
atomical integrity in the temporal lobe and hippocampal 
regions are highly impacted in both illness,62 yet the field 
lacks robust comparative studies to determine if  the 
2 illnesses intersect as Kraepelin once delineated with 
conviction. This question is revived by the evidence of 
a higher risk for developing dementia in SZ.1 Using 
modern imaging methods, our findings provide tantal-
izing evidence for a relationship between SZ and AD at 
the white matter level.
In AD, white matter deficits can be secondary to neu-
ronal amyloid-β and amyloid precursor protein accumu-
lation63 in the frontal and temporal lobes that eventually 
impact the associative tracts.64,65 In SZ, white mater 
deficits may be due to the abnormal expression of oligo-
dendrocyte lineage genes or oligodendrocyte cellular dys-
functions.66,67 The reciprocal rise in RVI-SZ in AD and 
RVI-AD in SZ may reflect different underlying pathology 
that converges on similar white matter structures as the 
disorders progress.
Conversely, there are arguments for the sharing of etio-
logical mechanisms between 2 disorders. For example, the 
frontal white matter has high metabolic demands and is 
vulnerable to cardiovascular risks.68,69 SZ patients have a 
shorter lifespan, and the leading cause of their premature 
mortality is cardiovascular diseases.70 In parallel, vascular-
related white matter damage predicts the development of 
AD, leading to the emerging 2-hit theory on AD etiology, 
whereby vascular insults constitute the first hit while the 
accumulation of amyloid-β is the second.71,72 Therefore, 
cardiovascular risks may present a common etiology to 
explain the shared white matter deficit patterns.
Another question is whether the overlapping white 
matter regional deficit patterns in AD and SZ are re-
lated to general cognitive deficits and, therefore, nonspe-
cific. However, the correlation between regional deficit 
patterns in SZ and MCI was not significant (figure 4B). 
Individuals with MCI have an unfavorable aging trajec-
tory that leads to deficits in the FX,73,74 similar to AD and 
SZ. However, MCI patients showed minimal deficits in 
the ACR, GCC, BCC, and other associative tracts. The 
specificity testing suggests that the sharing of deficit pat-
terns between SZ and AD is not simply due to age-related 
cognitive decline as in MCI.
We also observed that RVI-AD was positively correl-
ated with age in SZ (figures  3A and 3B), such that the 
similarity to AD in SZ patients became stronger with age. 
This finding is consistent with recent “brain age” ana-
lyses showing that SZ had the largest accelerated aging 
rate among all psychiatric illnesses (Cohen’s d  =  0.54), 
and AD has an even larger effect size (d = 1.03).75 This 
may argue for the sharing of an age-related underlying 
pathology for the 2 otherwise distinct illnesses.
Our study is limited by the lack of longitudinal data 
to confirm if the RVI-AD score would track the risk for 
dementia and cognitive decline in SZ patients. Only FA 
was used to index white matter abnormalities and other 
diffusion parameters were not explored. We chose FA 
as it shows a higher sensitivity to SZ deficits compared 
with other parameters.39 Additionally, the testing of RVI-
cognition associations was limited by differences in the 
cognitive tests administered across the discovery and rep-
lication samples, especially the ADNI sample where the 
cognitive tests were designed for the diagnosis of dementia 
and, therefore, may suffer from score compression in 
non-AD subjects due to ceiling effects. Lastly, a potential 
explanation for the similarity of WM deficits in SZ and AD 
is the use of antipsychotic medications in both disorders. 
However, we consider this to be unlikely due to (1) the lack 
of association between RVI and medication dose and (2) 
the elevation of RVI-SZ values at the treatment initiation 
stage.32 The latter suggests that white matter deficits are al-
ready established in patients prior to the treatment onset.
A shared aim in SZ and AD research is to discover 
therapeutic interventions that can restore, prevent, or 
slow down the progression of cognitive deficits in these 
diseases. We demonstrated an unambiguous overlap in 
white matter deficit patterns between SZ and AD. This 
pattern was associated with the disease-related cognitive 
deficits and appeared to be disease-specific. Development 
of future treatments and therapies to prevent and treat 
cognitive deficits in SZ and AD should consider targeting 
white matter-related mechanisms.
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